Recent discussions on X about Hims & Hers Health (HIMS) have centered on the company’s innovative telehealth model and its potential to disrupt the traditional healthcare industry. Many users are intrigued by the company’s cash-pay approach, which bypasses insurance, and its rapid revenue growth, with some pointing to its expansion into areas like weight management as a key growth driver. The buzz has also been fueled by speculation of a possible short squeeze due to high short interest and growing retail investor attention.
While enthusiasm runs high, there are also voices of caution on the platform, with some questioning whether the company’s ambitious goals can truly redefine healthcare or if the risks are being underestimated. Posts highlight the binary nature of the investment—either a transformative success or a significant failure—as the company aims to become a full-stack consumer health platform. This polarized debate keeps the conversation engaging, reflecting both optimism and skepticism about HIMS’ future trajectory.
Note: This discussion summary was generated from an AI condensation of post data.
Hims & Hers Health Insider Trading Activity
Hims & Hers Health insiders have traded $HIMS stock on the open market 112 times in the past 6 months. Of those trades, 0 have been purchases and 112 have been sales.
Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:
- ANDREW DUDUM (Chief Executive Officer) has made 0 purchases and 46 sales selling 1,297,836 shares for an estimated $60,616,323.
- MELISSA BAIRD (Chief Operating Officer) has made 0 purchases and 19 sales selling 235,377 shares for an estimated $9,022,088.
- OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 15 sales selling 138,873 shares for an estimated $5,862,603.
- MICHAEL CHI (Chief Commercial Officer) has made 0 purchases and 10 sales selling 77,768 shares for an estimated $4,181,528.
- SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 14 sales selling 47,607 shares for an estimated $2,206,422.
- IRENE BECKLUND (PAO) has made 0 purchases and 7 sales selling 32,088 shares for an estimated $1,411,579.
- PATRICK HARRISON CARROLL (Chief Medical Officer) sold 23,287 shares for an estimated $798,976
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Hims & Hers Health Hedge Fund Activity
We have seen 274 institutional investors add shares of Hims & Hers Health stock to their portfolio, and 227 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 5,862,886 shares (-19.5%) from their portfolio in Q1 2025, for an estimated $173,248,281
- D. E. SHAW & CO., INC. added 5,390,213 shares (+841.7%) to their portfolio in Q1 2025, for an estimated $159,280,794
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 4,332,982 shares (-68.7%) from their portfolio in Q1 2025, for an estimated $128,039,618
- SRS INVESTMENT MANAGEMENT, LLC added 4,000,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $118,200,000
- ICONIQ CAPITAL, LLC removed 2,874,769 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $84,949,423
- GOLDMAN SACHS GROUP INC added 2,738,501 shares (+49.4%) to their portfolio in Q1 2025, for an estimated $80,922,704
- WELLINGTON MANAGEMENT GROUP LLP removed 2,569,041 shares (-75.1%) from their portfolio in Q1 2025, for an estimated $75,915,161
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Hims & Hers Health Analyst Ratings
Wall Street analysts have issued reports on $HIMS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 06/04/2025
- Citigroup issued a "Sell" rating on 05/06/2025
- B of A Securities issued a "Underperform" rating on 04/29/2025
- Canaccord Genuity issued a "Buy" rating on 02/19/2025
To track analyst ratings and price targets for Hims & Hers Health, check out Quiver Quantitative's $HIMS forecast page.
Hims & Hers Health Price Targets
Multiple analysts have issued price targets for $HIMS recently. We have seen 9 analysts offer price targets for $HIMS in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Jailendra Singh from Truist Securities set a target price of $48.0 on 07/17/2025
- Craig Hettenbach from Morgan Stanley set a target price of $40.0 on 06/11/2025
- Ryan MacDonald from Needham set a target price of $65.0 on 06/04/2025
- Korinne Wolfmeyer from Piper Sandler set a target price of $39.0 on 05/06/2025
- Daniel Grosslight from Citigroup set a target price of $30.0 on 05/06/2025
- Allen Lutz from B of A Securities set a target price of $26.0 on 04/29/2025
- Jonna Kim from TD Cowen set a target price of $30.0 on 04/29/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
